CPRX - Catalyst Pharmaceuticals, Inc.
| Previous Close | 2.62 |
| Open | 2.59 |
| Bid | 2.10 x 2000 |
| Ask | 2.80 x 900 |
| Day's Range | 2.56 - 2.76 |
| 52 Week Range | 0.94 - 3.20 |
| Volume | 758,118 |
| Avg. Volume | 564,290 |
| Market Cap | 233.37M |
| Beta | 1.24 |
| PE Ratio (TTM) | -13.53 |
| EPS (TTM) | -0.2 |
| Earnings Date | Nov 7, 2017 - Nov 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.44 |
- GlobeNewswire•7 days ago
Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum
CORAL GABLES, Fla., Oct. 16, 2017-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular ...
- GlobeNewswire•2 months ago
Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities
--FDA grants Special Protocol Assessment agreement for Phase 3 MuSK-MG trial--. --Enrollment for second Phase 3 trial for LEMS nearing completion--. --Expected NDA submission for Firdapse moves from end ...
- ACCESSWIRE•2 months ago
Investor Network: Catalyst Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 10, 2017 / Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 10, 2017 at ...
- Associated Press•2 months ago
Catalyst reports 2Q loss
On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 5 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- GlobeNewswire•2 months ago
Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update
CORAL GABLES, Fla., Aug. 09, 2017-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular ...
- GlobeNewswire•3 months ago
Catalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10th, 2017
CORAL GABLES, Fla., Aug. 01, 2017-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular ...
- Accesswire•3 months ago
Today's Research Reports on Trending Tickers: Nektar Therapeutics and Catalyst Pharmaceuticals Inc.
NEW YORK, NY / ACCESSWIRE / July 12, 2017 / After a dismal 2016, the Biotech Industry has rallied back in 2017 as regulation fears have subsided. The iShares NASDAQ Biotechnology Index ETF and the SPDR ...
- Investopedia•5 months ago
Three Junior Biotechs Ready to Run
Junior biotechs are attracting strong speculative interest that could offer outstanding returns for traders with well-honed risk management skills.
- Accesswire•5 months ago
Investor Network: Catalyst Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 11, 2017 / Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) will be discussing their earnings results in their Q1 Earnings Call to be held May 11, 2017 at 8:30 AM Eastern ...
- Associated Press•5 months ago
Catalyst reports 1Q loss
On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 6 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- Zacks•6 months ago
What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?
Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11.
- Accesswire•7 months ago
Catalyst Pharmaceuticals and ZIOPHARM Oncology Bounce Up On FDA Phase News
NEW YORK, NY / ACCESSWIRE / March 28, 2017 / As FDA Phase trials continue, the two biopharmaceutical companies received positive feedback from the FDA and investors responded by adding shares of stock ...
- Accesswire•7 months ago
Financials of Aurinia Pharmaceuticals and Catalyst Pharmaceuticals are Getting Stability
NEW YORK, NY / ACCESSWIRE / March 21, 2017 / Both companies achieved their stability in different ways, but still achieved the same end. That achievement was reflected in their rise in stock prices at ...
- Insider Monkey•7 months ago
Catalyst Pharmaceuticals Inc (CPRX): Here’s What’s Next
After struggling throughout the latter half of 2016 with various development and regulatory pressures, Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has finally found some reprieve. Said reprieve comes in the form of some data just put out relating to the company’s lead development candidate (although not related to said candidate’s lead indication directly) and Catalyst is running […]
- Associated Press•7 months ago
Catalyst reports 4Q loss
On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 5 cents. For the year, the company reported that its loss widened to $18.1 million, or 22 cents per share. In the final ...
- Investopedia•7 months ago
Catalyst Pharma Neuromuscular Drug Succeeds In Study
Catalyst stock hit a 52-week high after its Firdapse drug reported positive study results.
- Insider Monkey•7 months ago
Here’s Why Traders Are Piling Into These Five Stocks
All three major indexes are in the green today as investors look forward to today’s FOMC meeting decision. Among the stocks that are also in bull-mode are Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), Capital Bank Financial Corp (NASDAQ:CBF), Msci Inc (NYSE:MSCI), Finisar Corporation (NASDAQ:FNSR), and Whiting Petroleum Corp (NYSE:WLL). Let’s find out why traders are hitting the buy […]
